Prof. Suzanne Turner
|
 |
| Research Topic | Leukaemia and Lymphoma Research |
| Research Interest | Suzanne Turner, PhD is a Senior Lecturer in tumour biology and pathology for more than 10 years. ST directs a research group investigating mechanism of ALK-induced malignancies and has contributed significantly to our understanding of the carcinogenic process. |
| Publications | Publication Link |
| Contact | Division of Molecular Histopathology
Lab Block Level 3, Box 231 Addenbrooke’s Hospital Cambridge, CB2 0QQ, UK Telephone: +44 (0)1223 762655 Email: sdt36@cam.ac.uk |
Dr. Olaf MerkelMedical University Vienna |
 |
| Research Topic | Molecular profiling and apoptosis regulation in lymphoma |
| Research Interest | Olaf Merkel is a lecturer in cancer therapeutics and an experienced biochemist. His main research interests are B and T-cell lymphomas. The focus of his group are non-coding RNAs, in particular miRNA and their impact on oncogenesis and cell survival. In particular, he is interested in the role of the oncogenic miR-155 and miR-17-92 clusters. Moreover, recently he became interested in cytokine regulation by BATF and cJUN in T-cell lymphomas. Also how cytokine signals are then transduced to the nucleus by the JAK/STAT pathway. Kinases in this pathway are potential therapeutic targets. |
| Publications | Publication Link |
| Contact | Clinical Institute for Pathology
Medical University of Vienna Währinger Gürtel,18-20, A-1090 Vienna, Austria Phone: +43 1 4040036610 Email: olaf.merkel@meduniwien.ac.at |
Dr. Gerda EggerMedical University of Vienna |
 |
| Research Topic | Epigenetics of ALK dependent cancers |
| Research Interest | Gerda Egger is lecturer on epigenetics and tumour biology since 2009. She directs a research group studying the impact of epigenetics in different diseases including cancer. Using mouse models we are trying to understand how epigenetic aberrations are generated and how they can be reversed and remodelled. We are using genome-scale analyses to define targets of differential DNA methylation in patient samples to define epigenetic biomarkers and to discover epigenetic drivers of different pathologies. |
| Publications | Publication Link |
| Contact | Clinical Institute of Pathology
Währinger Gürtel 18-20 1090 Vienna, Austria Phone: +43 1 40400 63890 Email: gerda.egger@meduniwien.ac.at |
Prof. Lukas Kenner
|
 |
| Research Topic | AP-1 in Lymphoma formation |
| Research Interest |
Lukas Kenner is board certified pathologist and an internationally acknowledged expert in comparative pathology. His research interest is the exploration of molecular mechanisms in neoplastic disease, their functional relevance for tumor progression and potential for clinical i8mprovements through diagnostic and prognostic measures. He has generated several transgenic mouse models for investigating the roles of AP-1 and PDGFRB in NPM-ALK transgenic mice. |
| Publications | Publication Link |
| Contact | Ludwig Boltzmann Institute for Cancer Research (LBI-CR)
Währingerstrasse 13A phone: +43 1 427764111 email: Lukas.kenner@lbicr.lbg.ac.at |
Prof. Šárka Pospíšilová,
|
 |
 |
| Research Topic | Genomics of lymphoproliferative disorders; role of p53 abnormalities in cancer |
| Research Interest | Prof. S. Pospisilova is head of the research center of Molecular Medicine in CEITEC, MU and also works in the department of Internal Medicine – Hematology and Oncology in the University Hospital Brno. She coordinates national and international research projects in leukaemia and lymphoma and is a member of the board of the European Research Initiative on CLL (ERIC) within the European Leukaemia Net. Her research group studies the genomic background of ALK-related malignancies (with application of NGS and array technologies) and the role of the p53 pathway and microRNAs in these tumours.
Characterization of ALK role in paediatric tumours specifically in neuroblastoma and rhabdomyosarcoma. Introduction of high-throughput analyses of human genomes for diagnostic tests.Study of neuroblastoma and other paediatric CNV (copy number variation) malignancies as epigenetic diseases with aim to better understand role of epigenome in ALK-induced malignancies in general. Identification of potential therapeutic targets in relapsed or refractory paediatric malignancies applicable in clinical practice. |
| Publications | Publication Link (SP) |
| Contact | CEITEC
Kamenice 753/5 Brno – Bohunice 625 00, Czech Republic Phone: +420532234622 E-mail: sarka.pospisilova@ceitec.muni.cz |
Prof. Falko Fend,
|
 |
 |
| Research Topic | Molecular Hematopathology |
| Research Interest | Prof. Falko Fend is head of the Department of Pathology and has a long track record in lymphoma research, molecular pathology and as a diagnostic hematopathologist. Prof. Quintanilla-Martinez de Fend, senior staff member and group leader, is a renowned hematopathologist with a long track record in lymphoma research and is an active leading member of international societies and groups in the field. Our research interests include the pathobiology of ALCL, genetics of early stages of lymphoma and the advancement of molecular diagnostics in hematopathology. |
| Publications | Publication Link (FF) |
| Contact | Institute of Pathology and Neuropathology
University Hospital Tuebingen Eberhard-Karls-University Liebermeisterstrasse 8 72076 Tuebingen, Germany Phone: 0049/7071-29-82266 email: falko.fend@med.uni-tuebingen.de |
Prof. Carlo Gambacorti Passerini
|
 |
| Research Topic | Clinical research into disease mechanisms of neoplastic disease |
| Research Interest |
Prof. Carlo Gambacorti-Passerini is a leading physician in the field of oncogenic fusion proteins and tyrosine kinase inhibitors. He has contributed significantly to the development of imatinib for the treatment of CML and successfully pioneered an ALK+ lymphoma patient therapy with ALK inhibitors. His research centers on identifying the molecular pathogenesis of hematological cancers using genome sequencing. He is interested in molecular mechanisms governing the transition from chronic phase to blast crisis in CML. In addition he is engaged in target validation of oncogenic fusion genes, structural characterization and screening of small-molecule inhibitors and new tyrosine kinase inhibitors to overcome therapy resistance in patients with ALK+ lymphomas. |
| Publications | Publication Link |
| Contact | Via Pergolesi 33
20900 Monza, Italy Phone: 0039 0392339553 Email: carlo.gambacorti@unimib.it |
Dr. Sylvie GiuriatoThe Cancer Research Centre of Toulouse (CRCT) |
 |
| Research Topic | RNA biology in hematological cancers |
| Research Interest | Dr. Sylvie Giuriato explores the expression profiles and functions of microRNAs, snoRNAs and lncRNAs in hematological malignancies (including anaplastic large cell lymphoma) . Recently, she has focused on the role of autophagy following crizotinib treatment. The goal is to pursue understanding the role and the regulation (in particular post-transcriptional regulation through microRNAs and/or RNA-Binding proteins) of this process both in basal conditions and following targeted-, chemo- and immuno-therapies. |
| Publications | Publication Link |
| Contact | UMR1037 INSERM-UPS-ERL5294 CNRS
Team 7: RNA biology in hematological cancers Oncopole de Toulouse, Entrée C, 2 avenue Hubert Curien CS53717 31037 TOULOUSE Cedex 1 – FRANCE phone: 0033-5-82-74-15-75 |
Dr. Stephan Mathas
|
 |
| Research Topic | Mechanisms of transformation in lymphoma |
| Research Interest | Stephan Mathas works as an MD treating in particular patients suffering from malignant lymphomas and group leader at the Max-Delbrück-Centre for Molecular Medicine. His research focuses on the pathogenesis of classical Hodgkin lymphoma and ALCL, for which his laboratory has already identified key molecular defects. |
| Publications | Publication Link |
| Contact | Institute for Hematology, Oncology and Tumorimmunology
Charité University Medical School Campus Virchow-Klinikum 13353 Berlin, Germany Phone: 0049 30 94 06 – 28 63 Email: stephan.mathas@charite.de |
Dr. Roberto ChiarleUniversity of Torino |
 |
| Research Topic | In vivo models of ALK-driven tumors and ALK-targeted immunotherapy |
| Research Interest |
Roberto Chiarle has wide expertise in cellular biology, immunology, and molecular biology. He holds clinical qualifications for haematopathology and is currently the recipient of a double appointment as Full Professor and clinical physician at the University of Torino and as Associate Professor at Harvard Medical School. RC is a pioneer in the field of ALK-related lymphoma having generated one of the first mouse models of ALK-induced ALCL. His research aims at therapeutic targeting of ALK by means of specific inhibitors, drugs and immunotherapy. His objectives are therefore to improve our understanding of the molecular mechanisms of
|
| Publications | Publication Link |
| Contact | Department of Molecular Biotechnology and Health Sciences
University of Torino Via Santena, 7 – 10126 Torino, ITALY Phone: +39 011.633.6861 Email: roberto.chiarle@unito.it |
Prof. Wilhelm Woessmann,
|
 |
 |
| Research Topic | Molecular diagnosis of childhood ALCL; Immune response to ALK in ALCL |
| Research Interest | Wilhelm Woessmann is a paediatric oncologist, co-chair of the NHL-BFM study group and an active member of the European paediatric NHL study group (EICNHL). His translational research includes biological risk factors, molecular biology and immune response against ALK in children with ALCL. |
| Publications | Publication Link |
| Contact |
Dept of Pediatric Hematology and Oncology Justus-Liebig-University Feulgenstr. 12 35392 Giessen Phone: +49- (0) 641-985-43462 or -43400 Email: wilhelm.woessmann@paediat.med.uni-giessen.de |
Dr. Laurence Brugieres,
|
 |
| Research Topic | Immunology of ALCL |
| Research Interest | Laurence Brugieres, MD is a paediatric oncologist involved in ALCL trials since 1999. She is engaged in a research programme devoted to biological mechanisms involved in immunogenicity of ALCL in children and investigates immune responses against ALK according to the type of treatment given to the patients. |
| Publications | Publication Link |
| Contact | Maison du projet
39, rue Camille Desmoulins 94 800 Villejuif Phone: + 33 (0)1 42 11 50 05 Email: Laurence.brugieres@gustaveroussy.fr |
Prof. Bengt Hallberg,
|
 |
 |
| Research Topic | Mechanisms behind the oncogene ALK in cell and mouse model systems |
| Research Interest | Bengt Hallberg has been working with receptor tyrosine kinase-mediated signalling since the beginning of the 1990’s. Recently his research has been addressing the role of ALK in the pathogenesis of neuroblastoma and has shown a dependence on ALK for MYCN transcription. He is investigating the function and importance of ALK RTK’s and differences in constitutively active ALK RTK mediated signalling at the molecular level as compared with wild type ALK in relevant cell models. This work is also carried out in mouse models which we have developed in with the aim of addressing ALK signalling in vivo.
Our laboratory is investigating signal transduction during developmental processes employing Drosophila melanogaster and mouse model systems. Our aim is to understand the importance and function of the ALK receptor tyrosine kinase during both normal and pathological developmental process. |
| Publications | Publication Link (BH) |
| Contact | Medicinaregatan 9 a
413 90, Göteborg Phone: +46 31 7863815 Email: bengt.hallberg@gu.se |
Prof. Justus Duyster,
|
 |
 |
| Research Topic | Identification and Eradication of ALCL-Lymphoma Stem cells |
| Research Interest | Prof. Justus Duyster is head of Medical Clinic for Hematology, Oncology and stem cell transplantation and has a long track record in the field of lymphoma and leukemia research and oncogenic fusion proteins. The Duyster group has previously established a murine bone marrow transplantation model and showed that retroviral NPM-ALK transduction into murine bone marrow leads to a histocytic or plasmocytic disease depending on viral titre. To induce a T-lymhoid ALCL in mice, we currently expressed NPM-ALK in a spatio-temporal manner. We will use this model to study lymphoma stem cells in NPM-ALK driven lymphomas and the eradication of the Lymphoma initiating population. Moreover, our current research involves the signal-transduction and the crosstalk between the DNA-damage stress axis in lymphoma initiation and progression. |
| Publications | Publication Link (JD) |
| Contact | Prof. Dr. Justus Duyster/ Dr. Lena Illert
University Medical Center Freiburg Dept. of Hematology, Oncology and Stem Cell Transplantation Hugstetter Str. 55 79106 Freiburg, Germany Tel: 0761-270-34060 Fax: 0761-270-32060 |
Prof. Giorgio Inghirami
|
 |
| Research Topic | Biology of lymphoproliferative disorders |
| Research Interest |
The main interest of Dr. Inghirami’s laboratory involves the molecular and biological characterization of PTCL, in particular, Anaplastic Large Cell Lymphoma (ALCL). A major effort has been devoted to the development of innovative in vitro and in vivo models to test new compounds and preclinical protocols.The development of a functional genomics laboratory and more recently of a hPDT mouse facility led to the discovery of the several molecular mechanisms leading to Anaplastic Lymphoma Kinase – driven lymphomagenesis and to the discovery of targets which could be explored as sensitive molecules for innovative tailored therapies. Moreover, the transcriptional characterization of a large panel of PTCL has provided novel insights to the origin of ALCL and a diagnostic classifier for routine clinical analyses. Molecular cytogenetic analyses have recently identified a high-risk group of patients, supporting the rationale for the implementation of tailored up – front therapy for naive ALCL patients. |
| Publications | Publication Link |
| Contact | Department of Pathology
Hospital S. Giovanni Battista Università di Torino Via Santena 7, 10126 Torino, ITALY phone: +39 011 633 4623 Email: giorgio.inghirami@unito.it 525 East 68th Street, Starr Pavilion, 715 EMAIL: ggi9001@med.cornell.edu |
Prof. George Z. Rassidakis
|
 |
| Research Topic | Lymphoma and Leukaemia Research |
| Research Interest |
|
| Publications | Publication Link |
| Contact | Karolinska Institutet (KI), Institutionen för onkologi-patologi (OnkPat), K7
Avdelningen för klinisk Patologi and Cytology Karolinska Universitets Sjukhuset Radiumhemmet 2-tr 08-517 733 03 |
Prof. Pierre Brousset
|
 |
| Research Topic | RNA biology in hematological cancers |
| Research Interest | The research group of Pr Brousset explores the expression profiles and functions of microRNAs, snoRNAs and lncRNAs in hematological malignancies (including anaplastic large cell lymphoma) but also the interaction between non-coding RNA and RNA-binding proteins.Recently, part of the group has focused on the role of autophagy following crizotinib treatment. Our goal is to pursue understanding the role and the regulation (in particular post-transcriptional regulation through microRNAs and/or RNA-Binding proteins) of this process both in basal conditions and following targeted-, chemo- and immuno-therapies. |
| Publications | Publication Link |
| Contact | UMR1037 INSERM-UPS-ERL5294 CNRS
Team 7: RNA biology in hematological cancers Oncopole de Toulouse, Entrée C, 2 avenue Hubert Curien CS53717 31037 TOULOUSE Cedex 1 – FRANCE phone: 0033-5-82-74-15-75 |
|
|
Prof. Pierre Brousset,
|
| Research Topic | RNA biology in hematological cancers |
| Research Interest | The research group of Pr Brousset explores the expression profiles and functions of microRNAs, snoRNAs and lncRNAs in hematological malignancies (including anaplastic large cell lymphoma) but also the interaction between non-coding RNA and RNA-binding proteins.Recently, part of the group has focused on the role of autophagy following crizotinib treatment. Our goal is to pursue understanding the role and the regulation (in particular post-transcriptional regulation through microRNAs and/or RNA-Binding proteins) of this process both in basal conditions and following targeted-, chemo- and immuno-therapies. |
| Publications | Publication Link |
| Contact | UMR1037 INSERM-UPS-ERL5294 CNRS
Team 7: RNA biology in hematological cancers Oncopole de Toulouse, Entrée C, 2 avenue Hubert Curien CS53717 31037 TOULOUSE Cedex 1 – FRANCE phone: 0033-5-82-74-15-75 |
|
Dr. Roberto ChiarleUniversity of Torino |
| Research Topic | In vivo models of ALK-driven tumors and ALK-targeted immunotherapy |
| Research Interest |
Roberto Chiarle has wide expertise in cellular biology, immunology, and molecular biology. He holds clinical qualifications for haematopathology and is currently the recipient of a double appointment as Full Professor and clinical physician at the University of Torino and as Associate Professor at Harvard Medical School. RC is a pioneer in the field of ALK-related lymphoma having generated one of the first mouse models of ALK-induced ALCL. His research aims at therapeutic targeting of ALK by means of specific inhibitors, drugs and immunotherapy. His objectives are therefore to improve our understanding of the molecular mechanisms of
|
| Publications | Publication Link |
| Contact | Department of Molecular Biotechnology and Health Sciences
University of Torino Via Santena, 7 – 10126 Torino, ITALY Phone: +39 011.633.6861 Email: roberto.chiarle@unito.it |
|
Prof. Justus Duyster
|
| Research Topic | Leukemogenesis and autophagy in NPM-ALK driven lymphomas |
| Research Interest | Prof. Justus Duyster is head of Medical Clinic for Hematology, Oncology and stem cell transplantation and has a long track record in the field of lymphoma research and oncogenic fusion proteins. The Duyster group has previously established a murine bone marrow transplantation model and showed that retroviral NPM-ALK transduction into murine bone marrow leads to a histocytic or plasmocytic disease depending on viral titre.. To induce a T-lymhoid ALCL in mice, we currently expressed NPM-ALK in a spatio-temporal manner.tWe will use this model to study autophagy and current research involves NPM-ALK driven lymphomas and the crosstalk between the DNA-damage stress axis in lymphoma initiation and progression. |
| Publications | Publication Link |
| Contact | Prof. Dr. med. Justus Duyster
III. Medizinische Klinik Klinikum rechts der Isar Technische Universität München Telefon: 089/ 4140-4104 Telefax: 089/ 4140-4854 e-Mail: lena.illert@lrz.tum.de |
|
Dr. Gerda EggerMedical University of Vienna |
| Research Topic | Epigenetics of ALK dependent cancers |
| Research Interest | Gerda Egger is lecturer on epigenetics and tumour biology since 2009. She directs a research group studying the impact of epigenetics in different diseases including cancer. Using mouse models we are trying to understand how epigenetic aberrations are generated and how they can be reversed and remodelled. We are using genome-scale analyses to define targets of differential DNA methylation in patient samples to define epigenetic biomarkers and to discover epigenetic drivers of different pathologies. |
| Publications | Publication Link |
| Contact | Clinical Institute of Pathology
Währinger Gürtel 18-20 1090 Vienna, Austria Phone: +43 1 40400 63890 Email: gerda.egger@meduniwien.ac.at |
|
|
Prof. Falko Fend,
|
| Research Topic | Molecular Hematopathology |
| Research Interest | Prof. Falko Fend is head of the Department of Pathology and has a long track record in lymphoma research, molecular pathology and as a diagnostic hematopathologist. Prof. Quintanilla-Martinez de Fend, senior staff member and group leader, is a renowned hematopathologist with a long track record in lymphoma research and is an active leading member of international societies and groups in the field. Our research interests include the pathobiology of ALCL, genetics of early stages of lymphoma and the advancement of molecular diagnostics in hematopathology. |
| Publications | Publication Link (FF) |
| Contact | Institute of Pathology and Neuropathology
University Hospital Tuebingen Eberhard-Karls-University Liebermeisterstrasse 8 72076 Tuebingen, Germany Phone: 0049/7071-29-82266 email: falko.fend@med.uni-tuebingen.de |
|
Prof. Carlo Gambacorti Passerini
|
| Research Topic | Clinical research into disease mechanisms of neoplastic disease |
| Research Interest |
Prof. Carlo Gambacorti-Passerini is a leading physician in the field of oncogenic fusion proteins and tyrosine kinase inhibitors. He has contributed significantly to the development of imatinib for the treatment of CML and successfully pioneered an ALK+ lymphoma patient therapy with ALK inhibitors. His research centers on identifying the molecular pathogenesis of hematological cancers using genome sequencing. He is interested in molecular mechanisms governing the transition from chronic phase to blast crisis in CML. In addition he is engaged in target validation of oncogenic fusion genes, structural characterization and screening of small-molecule inhibitors and new tyrosine kinase inhibitors to overcome therapy resistance in patients with ALK+ lymphomas. |
| Publications | Publication Link |
| Contact | Via Pergolesi 33
20900 Monza, Italy Phone: 0039 0392339553 Email: carlo.gambacorti@unimib.it |
|
Bengt Hallberg
|
| Research Topic | Mechanisms behind the oncogene ALK in cell and mouse model systems |
| Research Interest | Bengt Hallberg has been working with receptor tyrosine kinase-mediated signalling since the beginning of the 1990’s. Recently his research has been addressing the role of ALK in the pathogenesis of neuroblastoma and has shown a dependence on ALK for MYCN transcription. He is investigating the function and importance of ALK RTK’s and differences in constitutively active ALK RTK mediated signalling at the molecular level as compared with wild type ALK in relevant cell models. This work is also carried out in mouse models which we have developed in with the aim of addressing ALK signalling in vivo. |
| Publications | Publication Link |
| Contact | Medicinaregatan 9 a
413 90, Göteborg Phone: +46 31 7863815 Email: bengt.hallberg@gu.se |
|
Prof. Giorgio Inghirami
|
| Research Topic | Biology of lymphoproliferative disorders |
| Research Interest |
The main interest of Dr. Inghirami’s laboratory involves the molecular and biological characterization of PTCL, in particular, Anaplastic Large Cell Lymphoma (ALCL). A major effort has been devoted to the development of innovative in vitro and in vivo models to test new compounds and preclinical protocols.The development of a functional genomics laboratory and more recently of a hPDT mouse facility led to the discovery of the several molecular mechanisms leading to Anaplastic Lymphoma Kinase – driven lymphomagenesis and to the discovery of targets which could be explored as sensitive molecules for innovative tailored therapies. Moreover, the transcriptional characterization of a large panel of PTCL has provided novel insights to the origin of ALCL and a diagnostic classifier for routine clinical analyses. Molecular cytogenetic analyses have recently identified a high-risk group of patients, supporting the rationale for the implementation of tailored up – front therapy for naive ALCL patients. |
| Publications | Publication Link |
| Contact | Department of Pathology
Hospital S. Giovanni Battista Università di Torino Via Santena 7, 10126 Torino, ITALY phone: +39 011 633 4623 Email: giorgio.inghirami@unito.it
525 East 68th Street, Starr Pavilion, 715 EMAIL: ggi9001@med.cornell.edu |
|
Prof. Andrea Janíková
|
| Research Topic | Clinical Lymphoma Research |
| Research Interest | Characterization of ALK role in paediatric tumours specifically in neuroblastoma and rhabdomyosarcoma. Introduction of high-throughput analyses of human genomes for diagnostic tests.Study of neuroblastoma and other paediatric CNV (copy number variation) malignancies as epigenetic diseases with aim to better understand role of epigenome in ALK-induced malignancies in general. Identification of potential therapeutic targets in relapsed or refractory paediatric malignancies applicable in clinical practice. |
| Publications | Publication Link |
| Contact | Faculty of Medicine
Masaryk University Complex University Hospital Brno Jihlavská 340/20 Brno – Bohunice 625 00 Czech Republic +420532 23 3877 ajanikova@fnbrno.cz |
|
Prof. Lukas Kenner
|
| Research Topic | AP-1 in Lymphoma formation |
| Research Interest |
Lukas Kenner is board certified pathologist and an internationally acknowledged expert in comparative pathology. His research interest is the exploration of molecular mechanisms in neoplastic disease, their functional relevance for tumor progression and potential for clinical i8mprovements through diagnostic and prognostic measures. He has generated several transgenic mouse models for investigating the roles of AP-1 and PDGFRB in NPM-ALK transgenic mice. |
| Publications | Publication Link |
| Contact | Ludwig Boltzmann Institute for Cancer Research (LBI-CR)
Währingerstrasse 13A phone: +43 1 427764111 email: Lukas.kenner@lbicr.lbg.ac.at |
|
Dr. Stephan Mathas
|
| Research Topic | Mechanisms of transformation in lymphoma |
| Research Interest | Stephan Mathas works as an MD treating in particular patients suffering from malignant lymphomas and group leader at the Max-Delbrück-Centre for Molecular Medicine. His research focuses on the pathogenesis of classical Hodgkin lymphoma and ALCL, for which his laboratory has already identified key molecular defects. |
| Publications | Publication Link |
| Contact | Institute for Hematology, Oncology and Tumorimmunology
Charité University Medical School Campus Virchow-Klinikum 13353 Berlin, Germany Phone: 0049 30 94 06 – 28 63 Email: stephan.mathas@charite.de |
|
Dr. Olaf MerkelMedical University Vienna |
| Research Topic | Molecular profiling and apoptosis regulation in lymphoma |
| Research Interest | Olaf Merkel is a lecturer in cancer therapeutics and an experienced biochemist. His main research interests are B and T-cell lymphomas. The focus of his group are non-coding RNAs, in particular miRNA and their impact on oncogenesis and cell survival. In particular, he is interested in the role of the oncogenic miR-155 and miR-17-92 clusters. Moreover, recently he became interested in cytokine regulation by BATF and cJUN in T-cell lymphomas. Also how cytokine signals are then transduced to the nucleus by the JAK/STAT pathway. Kinases in this pathway are potential therapeutic targets. |
| Publications | Publication Link |
| Contact | Clinical Institute for Pathology
Medical University of Vienna Währinger Gürtel,18-20, A-1090 Vienna, Austria Phone: +43 1 4040036610 Email: olaf.merkel@meduniwien.ac.at |
|
Prof. Ruth Palmer
|
| Research Topic | ALK function in Drosophila and mouse model systems |
| Research Interest | Our laboratory is investigating signal transduction during developmental processes employing Drosophila melanogaster and mouse model systems. Our aim is to understand the importance and function of the ALK receptor tyrosine kinase during both normal and pathological developmental process. |
| Publications | Publication Link |
| Contact | Medicinaregatan 9 a, Göteborg
Postal Address: Box 440, 40530 Göteborg Phone: +46 31 7863906+46 31 7863906 Email: ruth.palmer@gu.se |
|
Prof. Šárka Pospíšilová
|
| Research Topic | Genomics of lymphoproliferative disorders; role of p53 abnormalities in cancer |
| Research Interest | Prof. S. Pospisilova is head of the research center of Molecular Medicine in CEITEC, MU and also works in the department of Internal Medicine – Hematology and Oncology in the University Hospital Brno. She coordinates national and international research projects in leukaemia and lymphoma and is a member of the board of the European Research Initiative on CLL (ERIC) within the European Leukaemia Net. Her research group studies the genomic background of ALK-related malignancies (with application of NGS and array technologies) and the role of the p53 pathway and microRNAs in these tumours. |
| Publications | Publication Link |
| Contact | CEITEC
Kamenice 753/5 Brno – Bohunice 625 00, Czech Republic Phone: +420532234622 E-mail: sarka.pospisilova@ceitec.muni.cz |
|
Prof. George Z. Rassidakis
|
| Research Topic | Lymphoma and Leukaemia Research |
| Research Interest |
|
| Publications | Publication Link |
| Contact | Karolinska Institutet (KI), Institutionen för onkologi-patologi (OnkPat), K7
Avdelningen för klinisk Patologi and Cytology Karolinska Universitets Sjukhuset Radiumhemmet 2-tr 08-517 733 03 |
|
Prof. Suzanne Turner
|
| Research Topic | Leukaemia and Lymphoma Research |
| Research Interest | Suzanne Turner, PhD is a Senior Lecturer in tumour biology and pathology for more than 10 years. ST directs a research group investigating mechanism of ALK-induced malignancies and has contributed significantly to our understanding of the carcinogenic process. |
| Publications | Publication Link |
| Contact | Division of Molecular Histopathology
Lab Block Level 3, Box 231 Addenbrooke’s Hospital Cambridge, CB2 0QQ, UK Telephone: +44 (0)1223 762655 Email: sdt36@cam.ac.uk |